Optilume™ BPH Prostatic Drug Coated Balloon Dilation Catheter (EVEREST-I)

Evaluation of Optilume™ BPH Prostatic Drug Coated Balloon Dilation Catheter in the Treatment of Moderate-to-Severe Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia

A prospective, non-randomized study. The subjects will be enrolled and treated with the Optilume BPH Prostatic DCB Dilation Catheter System at up to 8 clinical sites. The post-treatment follow-up visit can be up to 5 years.

The objective of the study is to evaluate the safety and efficacy of the Optilume™ BPH Prostatic Drug Coated Balloon Dilation Catheter System in the treatment of BPH.

Study Overview

• Status: Completed
• Conditions: Benign Prostatic Hyperplasia; Benign Prostatic Hypertrophy
• Intervention / Treatment: Device: Optilume™ BPH Prostatic DCB Dilation Catheter; Drug: Paclitaxel

Detailed Description

A prospective, non-randomized, multi-center study. The study will enroll up to 85 subjects to be enrolled and treated with the Optilume BPH Prostatic DCB Dilation Catheter System at up to 8 clinical sites. Subjects will be followed up post-treatment at Foley removal, and up to 1 year. The subjects may choose to be followed-up annually for 5 years or until study close, whichever comes first.

Study device is Optilume™ BPH Prostatic Drug Coated Balloon Dilation Catheter System.

Study primarily outcomes are measured by 1). Change in IPSS score at 3-month post-procedure follow-up; 2). Major device or procedure related complications at 3-month post-procedure follow-up.

• Study Type: Interventional
• Enrollment (Actual): 80
• Phase: Phase 2

Contacts and Locations

Study Locations

• Dominican Republic
  • La Romana, Dominican Republic
    • Centro Medico Dr. Canela, SRL
  • Santiago Province
    • Santiago de los Caballeros, Santiago Province, Dominican Republic
      • Union Medica Hospital
  • Santo Domingo Province
    • Santo Domingo Oeste, Santo Domingo Province, Dominican Republic
      • Urolaser SRL
• Panama
  • Panama City, Panama
    • Centro Especializado San Fernando
  • Urbanización Marbella Ciudad de Panamá
    • Panama City, Urbanización Marbella Ciudad de Panamá, Panama
      • Consultorios Royal Center

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 50 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

1. Male subject > 50 years of age who has moderate-to-severe LUTS (IPSS score of ≥ 13) and is a candidate for interventional therapy
2. LUTS felt to be secondary to an enlarged prostate (henceforth termed LUTS/BPH)
3. Peak urinary flow rate (Qmax) ≥ 5 mL/sec and ≤ 15 ml/sec with minimum voided volume of ≥ 125 ml
4. Post-void residual (PVR) ≤ 250 ml
5. Prostate volume 20 - 80 gm as determined by TRUS
6. Prostatic urethra length is 35 - 55 mm as determined by TRUS
7. Able to complete the study protocol in the opinion of the investigator

Exclusion Criteria:

1. Interested in maintaining fertility and unwilling to use protected sex for the first 30 days post treatment
2. Unwilling to abstain or use protected sex for ninety (90) days post treatment if sexual partner is of child bearing potential
3. Presence of a penile implant or stent(s) in the urethra or prostate
4. Any prior minimally invasive intervention (e.g. TUNA, Balloon, Microwave, Rezūm, UroLift) or surgical intervention of the prostate
5. PSA > 10 ng/ml unless prostate cancer is ruled out by biopsy. If PSA is > 4 ng/ml and ≤ 10 ng/ml, prostate cancer must be ruled out to the satisfaction of the investigator via additional tests including digital rectal exam (DRE) and/or biopsy
6. Confirmed or suspected malignancy of prostate or bladder
7. Active or history of epididymitis within the past 3 months
8. Previous pelvic irradiation or radical pelvic surgery
9. Documented active urinary tract infection (UTI) by culture or bacterial prostatitis within last year documented by culture (UTI is defined as >100,000 colonies per ml urine from midstream clean catch or catheterization specimen)
10. Visible hematuria with subject urine sample without known contributing factor
11. Neurogenic bladder or sphincter abnormalities or neurological disorders that might affect bladder or sphincter function
12. Previous or current diagnosis of urethral strictures, bladder neck contracture or detrusor muscle spasms
13. Use of beta blockers, antihistamines, anticonvulsants, or antispasmodics within 1 week prior to treatment unless there is documented evidence of stable dosing for last 6 months (no dose changes)
14. Use of alpha blockers, antidepressants, anticholinergics, androgens, daily tadalafil or gonadotropin-releasing hormonal analogs (prescribed for BPH) within 3 weeks prior to treatment
15. Use of 5-alpha reductase inhibitor within 6 months prior to treatment
16. Incidence of spontaneous urinary retention within 6 months prior to baseline assessment
17. Post-void residual volume > 250 ml or catheter dependent bladder drainage
18. Overactive bladder (OAB) or urge incontinence
19. Known poor detrusor muscle function (e.g. Qmax < 5 ml/sec)
20. Current bladder stones or prostatic calculi
21. Biopsy of prostate within 30 days prior to procedure or planned within 30 days following the procedure
22. History of cancer in non-genitourinary system which is not considered cured (except basal cell or squamous cell carcinoma of the skin). A potential participant is considered cured if there has been no evidence of cancer within five years
23. History of clinically significant comorbidities or presence of unstable conditions (e.g. cardiovascular, lung, renal [serum creatinine > 2.0 mg/dl], hepatic, bleeding disorders, or metabolic impairment) that may confound the results of the study or have a risk to subject per investigator's opinion
24. Any cognitive disorder that interferes with or precludes direct and accurate communication with the study investigator regarding the study or affects the ability to complete the study quality of life questionnaires
25. Expected life expectancy < one year
26. Unable or unwilling to sign the Informed Consent Form (ICF) and/or comply with all the follow-up requirements
27. Currently enrolled in or plan to enroll in another investigational clinical trial for any disease except for observational only study
28. In the opinion of the investigator, it is not in the subject's best interest to participate in the study
29. Current treatment with anti-coagulants (e.g., warfarin or enoxaparin) or anti-platelet medications other than aspirin (e.g., clopidogrel)
30. Anatomy, e.g. presence of false passage or size of meatus, is not suitable for treatment in this study
31. Device that corresponds with the subject's prostate size per the IFU is not available
32. Intravesical prostatic protrusion (IPP) > 1 cm
33. Current uncontrolled diabetes (hemoglobin A1c > 7%)
34. Unable or unwilling to provide all the protocol-required semen samples
35. Sensitivity to paclitaxel, on medication that may have negative interaction with paclitaxel, or contraindicated for systemic paclitaxel

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Optilume™ BPH Prostatic DCB Dilation Catheter; Optilume™ BPH Prostatic DCB treatment procedure	Device: Optilume™ BPH Prostatic DCB Dilation Catheter; BPH Prostatic DCB treatment - The Optilume BPH Prostatic DCB Dilation Catheter System should be prepared per the Instructions for Use (IFU).; Other Names: BPH Prostatic DCB; Drug: Paclitaxel; paclitaxel will release to adjacent tissue after the balloon inflated in the urethra; Other Names: drug coated balloon

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Therapeutic Responder at 3 Months	The proportion of subjects experiencing at least a 40% improvement in International Prostate Symptom Score (IPSS) scores from baseline to 3 months. The IPSS contains the well-validated, highly reliable and responsive American Urological Association symptom score (AUASS) assessment to identify the severity of BPH symptoms. The first seven questions in the IPSS address frequency, nocturia, weak urinary stream, hesitancy, intermittence, incomplete emptying, and urgency, and scored on a 6-point scale (0 to 5). The IPSS can be interpreted as follows: 0-7 mildly symptomatic, 8-19 moderately symptomatic, and 20-35 severely symptomatic.	90 days
Major Device/Procedure Related Complications	The proportion of subjects reporting a composite of device/procedure related severe urinary retention (lasting >14 days), unresolved stress urinary incontinence, or bleeding requiring transfusion.	90 days

Collaborators and Investigators

• Sponsor: Urotronic Inc.
• Investigators: Study Director: Jill Moland, Urotronic Inc.

Publications and helpful links

General Publications

• Pichardo M, Rijo E, Espino G, Lay RR, Estrella R, Gonzalez C, Fernandez M, Soriano D, Peralta IM, Kaplan SA. Durable benefit after treatment of obstructive benign prostatic hyperplasia with a novel drug-device combination product: 2-year outcomes from the EVEREST-I study. World J Urol. 2023 Aug;41(8):2209-2215. doi: 10.1007/s00345-023-04473-1. Epub 2023 Jun 24.

Study record dates

Study Major Dates

• Study Start (Actual): December 19, 2017
• Primary Completion (Actual): June 4, 2019
• Study Completion (Actual): May 25, 2024

Study Registration Dates

• First Submitted: January 30, 2018
• First Submitted That Met QC Criteria: February 3, 2018
• First Posted (Actual): February 6, 2018

Study Record Updates

• Last Update Posted (Actual): November 26, 2025
• Last Update Submitted That Met QC Criteria: November 13, 2025
• Last Verified: November 1, 2025

More Information

Terms related to this study

• Keywords: BPH
• Additional Relevant MeSH Terms: Urogenital Diseases; Genital Diseases; Genital Diseases, Male; Prostatic Diseases; Male Urogenital Diseases; Prostatic Hyperplasia; Organic Chemicals; Hydrocarbons; Cycloparaffins; Hydrocarbons, Alicyclic; Hydrocarbons, Cyclic; Terpenes; Taxoids; Cyclodecanes; Diterpenes; Paclitaxel
• Other Study ID Numbers: PR1051

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: Yes
• product manufactured in and exported from the U.S.: Yes